Effect of rhG-CSF Combined With Decitabine Prophylaxis on Relapse of Patients With High-Risk MRD-Negative AML After HSCT: An Open-Label, Multicenter, Randomized Controlled Trial

Lei Gao,Yanqi Zhang,Sanbin Wang,Peiyan Kong,Yi Su,Jiong Hu,Ming Jiang,Hai Bai,Tao Lang,Jishi Wang,Li Liu,Tonghua Yang,Xiaobing Huang,Fang Liu,Shifeng Lou,Yao Liu,Cheng Zhang,Hong Liu,Li Gao,Jia Liu,Lidan Zhu,Qin Wen,Ting Chen,Ping Wang,Jun Rao,Min Mao,Cunbang Wang,Xianlin Duan,Le Luo,Xiangui Peng,Kaniel Cassady,Jiang F. Zhong,Xi Zhang
DOI: https://doi.org/10.1200/jco.19.03277
IF: 45.3
2020-10-28
Journal of Clinical Oncology
Abstract:PURPOSE Relapse is a major cause of treatment failure after allogeneic hematopoietic stem-cell transplantation (allo-HSCT) for high-risk acute myeloid leukemia (HR-AML). The aim of this study was to explore the effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) combined with minimal-dose decitabine (Dec) on the prevention of HR-AML relapse after allo-HSCT. PATIENTS AND METHODS We conducted a phase II, open-label, multicenter, randomized controlled trial. Two hundred four patients with HR-AML who had received allo-HSCT 60-100 days before randomization and who were minimal residual disease negative were randomly assigned 1:1 to either rhG-CSF combined with minimal-dose Dec (G-Dec group: 100 μg/m 2 of rhG-CSF on days 0-5 and 5 mg/m 2 of Dec on days 1-5) or no intervention (non–G-Dec group). The primary outcome was relapse after transplantation, and the secondary outcomes were chronic graft-versus-host disease (cGVHD), safety of the treatment, and survival. RESULTS The estimated 2-year cumulative incidence of relapse in the G-Dec group was 15.0% (95% CI, 8.0% to 22.1%), compared with 38.3% (95% CI, 28.8% to 47.9%) in the non–G-Dec group ( P < .01), with a hazard ratio (HR) of 0.32 (95% CI, 0.18 to 0.57; P < .01). There was no statistically significant difference between the G-Dec and non–G-Dec groups in the 2-year cumulative incidence of cGVHD without relapse (23.0% [95% CI, 14.7% to 31.3%] and 21.7% [95% CI, 13.6% to 29.7%], respectively; P = .82), with an HR of 1.07 (95% CI, 0.60 to 1.92; P = .81). After rhG-CSF combined with minimal-dose Dec maintenance, increasing numbers of natural killer, CD8+ T, and regulatory T cells were observed. CONCLUSION Our findings suggest that rhG-CSF combined with minimal-dose Dec maintenance after allo-HSCT can reduce the incidence of relapse, accompanied by changes in the number of lymphocyte subtypes.
oncology
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: in patients with high - risk acute myeloid leukemia (HR - AML) after allogeneic hematopoietic stem cell transplantation (allo - HSCT), recurrence is a major cause of treatment failure. This study aims to explore the effect of recombinant human granulocyte colony - stimulating factor (rhG - CSF) combined with low - dose decitabine (Dec) in preventing recurrence in HR - AML patients after allo - HSCT. Specifically, this study evaluated the impact of rhG - CSF combined with low - dose Dec on the recurrence of high - risk acute myeloid leukemia patients after allo - HSCT through an open - label, multi - center, randomized controlled trial. The primary endpoint of the study was the recurrence situation after transplantation, and the secondary endpoints included chronic graft - versus - host disease (cGVHD), the safety of treatment, and survival rate. ### Main problem summary 1. **Recurrence prevention**: The main purpose of the study was to evaluate whether rhG - CSF combined with low - dose Dec could effectively reduce the recurrence rate of HR - AML patients after allo - HSCT. 2. **Safety and tolerance**: The study also focused on the safety and tolerance of this combined treatment. 3. **Immune response changes**: The study observed the changes in lymphocyte subsets during the treatment process, especially the changes in the numbers of natural killer cells (NK cells), CD8+ T cells, and regulatory T cells. ### Study design - **Participants**: 204 HR - AML patients who had received allo - HSCT and were negative for minimal residual disease (MRD - negative). - **Grouping**: Patients were randomly divided into two groups: the experimental group (G - Dec group) received rhG - CSF combined with low - dose Dec treatment, and the control group (non - G - Dec group) received no intervention. - **Treatment course**: Patients in the G - Dec group received 6 courses of treatment, with rhG - CSF 100 mg/m² (days 0 - 5) and Dec 5 mg/m² (days 1 - 5) in each course, once every 6 - 8 weeks. ### Main findings - **Recurrence rate**: The 2 - year cumulative recurrence rate of patients in the G - Dec group was 15.0% (95% CI, 8.0% to 22.1%), while that in the non - G - Dec group was 38.3% (95% CI, 28.8% to 47.9%), with a significant difference (HR = 0.32, 95% CI, 0.18 to 0.57; P <.01). - **cGVHD incidence**: There was no significant difference in the 2 - year cumulative cGVHD incidence between the two groups (23.0% in the G - Dec group and 21.7% in the non - G - Dec group, P =.81). - **Immune cell changes**: After treatment, the numbers of NK cells, CD8+ T cells, and regulatory T cells in patients in the G - Dec group increased. ### Conclusion The study results show that rhG - CSF combined with low - dose Dec maintenance treatment can significantly reduce the recurrence rate of HR - AML patients after allo - HSCT, accompanied by changes in the numbers of lymphocyte subsets, which may be helpful for obtaining graft - versus - leukemia effect and immune tolerance.